NASDAQ:VBIV - VBI Vaccines Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.94 +0.06 (+3.19 %)
(As of 08/20/2018 04:00 PM ET)
Previous Close$1.89
Today's Range$1.89 - $2.01
52-Week Range$1.78 - $5.10
Volume2,252 shs
Average Volume210,054 shs
Market Capitalization$122.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
VBI Vaccines logoVBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

Receive VBIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VBIV
CUSIPN/A
Phone617-830-3031

Debt

Debt-to-Equity Ratio0.14
Current Ratio2.75
Quick Ratio2.69

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$860,000.00
Price / Sales145.23
Cash FlowN/A
Price / CashN/A
Book Value$1.88 per share
Price / Book1.03

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-38,990,000.00
Net Margins-6,175.95%
Return on Equity-53.12%
Return on Assets-41.20%

Miscellaneous

Employees103
Outstanding Shares64,380,000
Market Cap$122.97 million

VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc (NASDAQ:VBIV) posted its quarterly earnings data on Thursday, July, 26th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.09. The biopharmaceutical company had revenue of $0.23 million for the quarter. VBI Vaccines had a negative return on equity of 53.12% and a negative net margin of 6,175.95%. View VBI Vaccines' Earnings History.

When is VBI Vaccines' next earnings date?

VBI Vaccines is scheduled to release their next quarterly earnings announcement on Monday, November, 12th 2018. View Earnings Estimates for VBI Vaccines.

What price target have analysts set for VBIV?

3 analysts have issued 1 year price objectives for VBI Vaccines' shares. Their predictions range from $10.00 to $12.00. On average, they expect VBI Vaccines' share price to reach $11.00 in the next year. This suggests a possible upside of 467.0% from the stock's current price. View Analyst Price Targets for VBI Vaccines.

What is the consensus analysts' recommendation for VBI Vaccines?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VBI Vaccines.

Who are some of VBI Vaccines' key competitors?

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the folowing people:
  • Mr. Jeff R. Baxter, CEO, Pres & Director (Age 57)
  • Dr. David Evander Anderson, Chief Scientific Officer (Age 48)
  • Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 63)
  • Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 53)
  • Ms. Nell Beattie, Chief Bus. Officer (Age 30)

Has VBI Vaccines been receiving favorable news coverage?

Media coverage about VBIV stock has been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. VBI Vaccines earned a news and rumor sentiment score of 0.05 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.86 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for VBI Vaccines.

Who are VBI Vaccines' major shareholders?

VBI Vaccines' stock is owned by many different of institutional and retail investors. Top institutional investors include Menora Mivtachim Holdings LTD. (5.37%), Cambridge Investment Research Advisors Inc. (2.02%), DAFNA Capital Management LLC (1.45%), Altshuler Shaham Ltd (1.38%), General American Investors Co. Inc. (1.34%) and Millennium Management LLC (0.82%). Company insiders that own VBI Vaccines stock include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Opko Health, Inc, Perceptive Advisors Llc and Steven Gillis. View Institutional Ownership Trends for VBI Vaccines.

Which major investors are selling VBI Vaccines stock?

VBIV stock was sold by a variety of institutional investors in the last quarter, including Cambridge Investment Research Advisors Inc. and DAFNA Capital Management LLC. View Insider Buying and Selling for VBI Vaccines.

Which major investors are buying VBI Vaccines stock?

VBIV stock was bought by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Millennium Management LLC, General American Investors Co. Inc., Jane Street Group LLC, Paloma Partners Management Co, Altshuler Shaham Ltd, LMR Partners LLP and Dimensional Fund Advisors LP. Company insiders that have bought VBI Vaccines stock in the last two years include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Opko Health, Inc, Perceptive Advisors Llc and Steven Gillis. View Insider Buying and Selling for VBI Vaccines.

How do I buy shares of VBI Vaccines?

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $1.94.

How big of a company is VBI Vaccines?

VBI Vaccines has a market capitalization of $122.97 million and generates $860,000.00 in revenue each year. VBI Vaccines employs 103 workers across the globe.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]


MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  291
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by MarketBeat.com Staff

Featured Article: Outstanding Shares

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel